The stock of Athira Pharma Inc. (NASDAQ:ATHA) last traded at $3.23, up 8.39% from the previous session.
Data from the available sources indicates that Athira Pharma Inc. (NASDAQ:ATHA) is covered by 6 analysts. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $33.00 and a low of $3.00, we find $5.50. Given the previous closing price of $2.98, this indicates a potential upside of 84.56 percent. ATHA stock price is now -0.41% away from the 50-day moving average and -51.84% away from the 200-day moving average. The market capitalization of the company currently stands at $112.69M.
In total, 3 analysts have assigned it a hold rating, and 3 have given it a buy rating. Brokers who have rated the stock have averaged $11.75 as their price target over the next twelve months.
With the price target maintained at $20, JMP Securities recently Upgraded its rating from Mkt Perform to Mkt Outperform for Athira Pharma Inc. (NASDAQ: ATHA). On July 07, 2022, Mizuho recently initiated its ‘Buy’ rating on the stock quoting a target price of $6, while ‘Stifel’ rates the stock as ‘Hold’.
In other news, PERCEPTIVE ADVISORS LLC, Director bought 1,101,362 shares of the company’s stock on Jun 30. The stock was bought for $3,293,072 at an average price of $2.99. Upon completion of the transaction, the Director now directly owns 4,797,278 shares in the company, valued at $15.5 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 29, Director PERCEPTIVE ADVISORS LLC bought 270,000 shares of the business’s stock. A total of $807,300 was incurred on buying the stock at an average price of $2.99. This leaves the insider owning 3,695,916 shares of the company worth $11.94 million. Insiders disposed of 19,995 shares of company stock worth roughly $64583.85 over the past 1 year. A total of 1.00% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in ATHA stock. A new stake in Athira Pharma Inc. shares was purchased by RA CAPITAL MANAGEMENT, L.P. during the first quarter worth $6,066,000. JEFFERIES GROUP LLC invested $650,000 in shares of ATHA during the first quarter. In the first quarter, AWH CAPITAL, L.P. acquired a new stake in Athira Pharma Inc. valued at approximately $371,000. P SCHOENFELD ASSET MANAGEMENT LP acquired a new stake in ATHA for approximately $323,000. TUDOR INVESTMENT CORP ET AL purchased a new stake in ATHA valued at around $136,000 in the second quarter. In total, there are 152 active investors with 63.90% ownership of the company’s stock.
With an opening price of $3.0600 on Friday morning, Athira Pharma Inc. (NASDAQ: ATHA) set off the trading day. During the past 12 months, Athira Pharma Inc. has had a low of $2.53 and a high of $16.65. The fifty day moving average price for ATHA is $3.2404 and a two-hundred day moving average price translates $6.6731 for the stock.
The latest earnings results from Athira Pharma Inc. (NASDAQ: ATHA) was released for Jun, 2022.
Athira Pharma Inc.(ATHA) Company Profile
Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company’s lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer’s disease, as well as is in Phase 2 clinical trials to treat Parkinson’s disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.